Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2012, Vol. 08 ›› Issue (06): 787 -791. doi: 10.3877/cma.j.issn.1673-5250.2012.06.032

Special Issue:

Review

Updated Progress of Gynecologic Complications in Breast Cancer With Adjuvant Therapy

Li-qin ZENG1(), Qi WANG2, Xiao-li SUN1, Xi-ping LUO1   

  1. 1. Department of Gynecology and Breast Surgery, Guangdong Women and Children Hospital, Guangzhou 510010, Guangdong Province, China
  • Received:2012-09-01 Revised:2011-11-01 Published:2012-12-01
  • Corresponding author: Li-qin ZENG
  • About author:
    (Corresponding author: ZENG Li-qin, Email: )

Adjuvant therapy including endocrine therapy, chemotherapy, prophylactic castration, hormone replacement therapy(HRT) of breast cancer in women frequently causes episodes of reproductive organs, which could be associated with proliferative changes of the endometrium, or even endometrial cancer. Chemotherapy for breast cancer is likely to negatively impact on ovarian function. A number of surveillances and interventions should be done. And we reviewed updated progress of gynecologic complications in breast cancer with adjuvant therapy, including contraception, preservation of infertility, breastfeeding following breast cancer.

[1]
Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008[J]. 2007-11-01].

URL    
[2]
Pagani O, Goldhirsch A. Breast cancer in young women: Climbing for progress in care and knowledge[J]. J Clin Oncol, 2006, 2(5):717-732.
[3]
Lhomme C, Pautier P, Zagame L, et al. Surveillance de l'endomètredes femmessous tamoxifène endometrial surveillance of women on tamoxifen[J]. Gynécol Obstét Fertil, 2003, 31(7-8):647-656.
[4]
Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials[J]. Lancet, 1998, 351:1451-1467.
[5]
Luo YF, Liu YH. Effect on endometrial by tamoxifen[J]. J Reprod Med, 2004, 13(6):338-341.
[6]
Wang C, Wang C, Huang H, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. CA A Cancer J Clin, 2002, 94(8):2192-2198.
[7]
Wen ZQ, Wang QX, Leng QG, et al. Clinical and pathological observations of oral norethisterone treatment of endometrial hyperplasia with menorrhagia[J].Progr Obstet Gynecol, 1999, 8(1):44-46.
[8]
Rose P, Brandewie E, Abdul-Karim F. Failure of megestrol acetate to reverse tamoxifen induced endometrial neoplasia: Two case reports[J]. Int J Gynecol Cancer, 1999, 9(5):362-364.
[9]
Montz F, Bristow R, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol, 2002, 186(4):651-657.
[10]
Gardner F, Konje J, Abrams K, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial[J]. Lancet, 2000, 356(9243):1711-1717.
[11]
Chan S, Tam W, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG[J].Int J Obstet Gynaecol, 2007, 114(12):1510-1515.
[12]
Gardner F, Konje J, Bell S, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial[J]. Gynecol Oncol, 2009, 114(3):452-456.
[13]
Chin J, Konje J, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Datab Syst Rev (Online), 2009, 4:20-23.
[14]
Wang S, Zha XM. Effect of tamoxifen on uterus and ovaries of postmenopausal breast cancer patients[J].Acta Univ Med Nanjing, 2001, 21(4):320-321.
[15]
Ji XQ, Sun GZ.Clinical analysis of ovarian cysts cause by tamoxifen treatment for breast cancer[J]. Clin Med China, 2003, 19(7):660-661.
[16]
Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: Reproductive and late health effects of treatment[J]. J Clin Oncol, 2003, 21(22):4184-4193.
[17]
Sun ZY, Shen K, Lang JH, et al. Effect on ovarian function in ovarian cancer patients after chemotherapy of preserve fertility function surgery[J]. Acta Acad Med Sin, 2003, 25(4):431-433.
[18]
Kil WJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast cancer research and treatment[J].Breast Cancer Res Treat, 2006, 96(3):245-250.
[19]
Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer[J]. Cancer Control, 2002, 9(6):466-472.
[20]
Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy[J]. Cur Opin Obstet Gynecol, 2005, 17(1):21-26.
[21]
Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a[J]. JNCI Monographs, 2005, 2005(34):40-43.
[22]
Gwyn K. Children exposed to chemotherapy in utero[J]. JNCI Monographs, 2005, 2005(34):69-71.
[23]
Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer[J]. Breast Cancer Res, 2007, 9(6):115.
[24]
Pritchard KI. Endocrine therapy of advanced disease[J]. Clin Cancer Res, 2003, 9(1):460-467.
[25]
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: Trial stopped[J]. Lancet, 2004, 363(9407):453-455.
[26]
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Nation Cancer Instit, 2005, 97(7):533-535.
[27]
Sestak I, Kealy R, Edwards R, et al. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms[J]. J Clin Oncol, 2006, 24(24):3991-3996.
[28]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial[J]. JAMA: J Am Med Assoc, 2002, 288(3):321-333.
[29]
Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Nation Cancer Instit, 2008, 100(7):475-482.
[30]
Madalinska JB, van Beurden M, Bleiker E, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy[J]. J Clin Oncol, 2006, 24(22):3576-3582.
[31]
Chiarelli AM, Kirsh VA, Klar NS, et al. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection[J]. Cancer Epidemiol Biomark Prevent, 2006, 15(10):1856-1862.
[32]
Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review[J]. Clin Therapeut, 2007, 29(2):230-241.
[33]
Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001[J]. Eur J Cancer, 2005, 41(10):1446-1452.
[34]
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer[J]. BMC cancer, 2006, 6(1):194.
[35]
Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer[J]. J Clin Oncol, 2004, 22(20):4174-4183.
[36]
Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women[J]. J Am College Surgeons, 2008, 206(6):1193-1203.
[37]
Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: Population based study[J]. BMJ, 2007, 334(7586):194.
[38]
Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence[J]. Cancer, 2004, 100(3):465-469.
[39]
Avilés A, Neri N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero[J]. Clin Lymphom, Myelom Leukem, 2001, 2(3):173-177.
[40]
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5):283-291.
[41]
Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma[J]. Cancer, 1999, 85(11):2424-2432.
[42]
Trinh XB, Tjalma WAA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril, 2008, 90(1):17-22.
[43]
Helewa MLP, Provencher D, Lea R, et al. Breast cancer, pregnancy, and breastfeeding[J]. J Obstet Gynaecol Canada, 2002, 24(2):164-180.
[44]
Sacchini V, Pinotti JA, Barros ACSD, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem[J]? J Am College Surgeons, 2006, 203(5):704-714.
[1] Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[2] Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[3] Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[4] Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[5] bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[6] Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[7] Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[8] Tao Chen, Hong Luo, JingJun Zhou. Risk factors of acute adverse reactions in elderly patients with esophageal cancer treated with radiotherapy alone and concurrent radiotherapy and chemotherapy[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 405-407.
[9] Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[10] Binkui Li. Conversion therapy for unresectable intrahepatic cholangiocarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 511-516.
[11] Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[12] Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[13] Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[14] Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[15] Xiaowu Zhang, Pengfei Tian, Wei Li, Qing Peng, Jingui Li, Deshen Li, Xiao Li. Comparison of subcutaneous central venous port via jugular and subclavian access: a retrospective study[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 301-304.
Viewed
Full text


Abstract